45,000 Shares in Abbott Laboratories $ABT Bought by Kentucky Farm Bureau Mutual Insurance Co

Kentucky Farm Bureau Mutual Insurance Co purchased a new stake in Abbott Laboratories (NYSE:ABT) in the second quarter, HoldingsChannel.com reports. The fund purchased 45,000 shares of the healthcare product maker’s stock, valued at approximately $4,083,000. Abbott Laboratories accounts for approximately 1.1% of Kentucky Farm Bureau Mutual Insurance Co’s investment portfolio, making the stock its 21st biggest holding.

A number of other large investors have also recently bought and sold shares of ABT. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the 4th quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the fourth quarter valued at approximately $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Abbott Laboratories Stock Performance

NYSE ABT opened at $112.63 on Friday. The firm’s fifty day moving average price is $102.61 and its two-hundred day moving average price is $100.22. The stock has a market cap of $194.89 billion, a PE ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABT. Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.